{
Bayer AG

Companies

}
growth prospects in the food for special medical purpose market
The Food for Special Medical Purpose market is poised for growth, driven by the rise in chronic illnesses and an aging population, particularly in Asia Pacific and Europe. Key players include Nestle, Danone Nutricia, and Abbott, with significant investments in R&D despite high costs and regulatory challenges. The market focuses on tailored nutritional solutions for infants, adults, and the elderly, reflecting evolving dietary needs.
openPR.com
United States Dollar Fresenius Kabi AG Targeted Medical Pharma, Inc. Danone Nutricia SL Nestlé S.A. Bayer AG Ajinomoto Co., Inc. AUT CHE JPN ESP USA DEU Nidhi Bhawsar Show more
Healthcare, Market Report
18:18 20.12.2024
global uveitis treatment market poised for significant growth by 2032
The Global Uveitis Treatment market is projected to grow from USD 725 million in 2024 to USD 1.28 billion by 2032, with a CAGR of 8.5%. The study covers various treatment types, including corticosteroids and biologic agents, and offers customization options for regional and application-specific analysis. Key players include Novartis, Pfizer, and AbbVie, with North America leading the market and Asia-Pacific identified as the fastest-growing region.
openPR.com
Pfizer Inc. Bayer AG Novartis AG Regeneron Pharmaceuticals, Inc. Merck & Co., Inc. CIPLA LTD Lupin Limited Hoffmann-La Roche AG Bausch Health Companies Inc. BIOGEN ABBVIE Alimera Sciences Inc. SAU ISR FRA RUS DEU TWN ARG ARE AUT TUR SGP NZL CHL USA BRA CAN ITA JPN IDN GBR ESP IND MYS COL AUS THA EGY VNM KOR PHL CHN ZAF MEX Nidhi Bhavsar Show more
Healthcare, Market Report
20:41 19.12.2024
Regeneron advances Eylea HD for retinal vein occlusion amid rising competition
Regeneron's Eylea HD has demonstrated noninferior visual acuity gains compared to the original Eylea in patients with macular edema following retinal vein occlusion, paving the way for a 2025 FDA filing. The drug, which generated $392 million in U.S. sales in Q3, faces competition from Amgen's biosimilar and Roche's Vabysmo, but its potential approval in RVO could boost sales further.
Fierce Pharma
United States Dollar Bayer AG Regeneron Pharmaceuticals, Inc. Hoffmann-La Roche AG Amgen Inc. USA George Yancopoulos Show more
Healthcare, Market Report
14:20 18.12.2024
biotech sector faces significant layoffs amid strategic shifts and acquisitions
In September, multiple biotech companies announced significant layoffs, with Inventprise cutting 7% of its workforce, bluebird bio reducing 25%, and Athira Pharma laying off 70% after a failed trial. Other notable reductions included Charles River Laboratories (3%), Cidara Therapeutics (30%), and Astellas Gene Therapies impacting around 100 employees. The trend reflects ongoing challenges in the biotech sector, with companies restructuring to focus on core projects and manage costs.
Fierce Biotech
Bristol-Myers Squibb Co Bayer AG Aker BioMarine AS CHE BEL USA NOR Paul B Eckburg Show more
Finance & Economy, Market Report
18:24 16.12.2024
global bisoprolol fumarate market poised for significant growth through 2032
The Global Bisoprolol Fumarate market is projected to grow from USD 1.3 billion in 2023 to USD 2.0 billion by 2032, with a CAGR of 7%. This medication, primarily used for hypertension and heart-related conditions, is expected to see increased demand driven by regulatory changes and market dynamics across various regions, particularly in Europe and Asia-Pacific. Key players include Merck, Pfizer, and Novartis, with a focus on understanding market trends and competitive strategies.
openPR.com
United States Dollar Merck & Co., Inc. Amgen Inc. Alkem Laboratories Limited Mylan Pharmaceuticals Inc. Aurobindo Pharma Limited Teva Pharmaceutical Industries Ltd Dr. Reddy's Laboratories Limited Glenmark Pharmaceuticals Limited CIPLA LTD Sandoz Group AG Pfizer Inc. Bayer AG Hikma Pharmaceuticals PLC AstraZeneca PLC Novartis AG Torrent Pharmaceuticals Limited Sanofi IND ROU BEL HUN DNK POL IDN SGP ARE BRA ZAF FRA THA MEX CZE GBR CHL AUT SAU SWE NOR NLD USA ARG MYS SVK CAN NZL LKA JPN DEU RUS KOR CHN VNM Nidhi Bhavsar Show more
Regulatory & Legal, Market Report
13:09 16.12.2024
global growth trends in the crispr and cas gene market to 2033
The global CRISPR and Cas gene market reached approximately $3.3 billion in 2023, growing at a CAGR of 20.38% since 2018. It is projected to expand to $8.8 billion by 2028 and $24.6 billion by 2033, driven by advancements in cancer therapeutics and gene therapy research. North America leads the market, accounting for 45.3% of the total value in 2023.
GlobeNewswire News Room
United States Dollar Bayer AG Bio-Rad Laboratories, Inc. Pluristem Therapeutics Inc. Genscript Biotech Corporation AstraZeneca PLC Qiagen N.V. Hologic, Inc. Cellectis S.A. Takara Bio Inc. Vertex Pharmaceuticals Inc Thermo Fisher Scientific Inc. Sigma-Aldrich Co. LLC Regeneron Pharmaceuticals Inc Editas Medicine Inc IND GBR ESP CAN AUS ITA IDN JPN BRA DEU FRA RUS KOR CHN USA Show more
Technology & Innovation, Market Report
15:27 13.12.2024
gilead appoints dietmar berger as new chief medical officer from sanofi
Gilead Sciences has appointed Dietmar Berger, M.D., Ph.D., as its new chief medical officer, recruiting him from Sanofi to replace Merdad Parsey. Berger, a cancer specialist with extensive experience at Genentech and Sanofi, will oversee Gilead's oncology pipeline, which is crucial for the company's growth strategy. He is set to start on January 2, 2024, as Gilead aims to enhance its oncology business amid significant clinical developments.
Fierce Biotech
United States Dollar Hoffmann-La Roche AG Gilead Sciences, Inc. Bayer AG Immunomedics Inc. Genentech Amgen Inc. Sanofi USA FRA John S. Reed Houman Ashrafian Daniel O'Day Merdad Parsey Dietmar Berger Show more
Healthcare, News Article
11:20 13.12.2024
DAX Breaks Winning Streak After Reaching New Record High
The DAX index ended its seven-session winning streak, closing at 20,346 after reaching a record high of 20,462. The market may face profit-taking or setbacks, with key support levels at 20,017 and 20,000, while resistance is noted at 20,400 and the record high.
4investors
Bayer AG DEU
Finance & Economy, Market Report
09:00 10.12.2024
UBS Maintains Neutral Rating on Bayer with Target Price of 22 Euros
UBS AG maintains a "Neutral" rating on Bayer shares with a target price of 22 euros, as the company faces a 40.1% decline since early 2024. Analyst Geoff Haire notes that a potential ceasefire in Ukraine could lower gas prices, benefiting the chemical sector. Bayer's shares rose 0.3% to EUR 20.08, indicating a 9.59% upside potential ahead of its Q4 2024 earnings report on March 5, 2025.
finanzen.ch
Euro Covestro AG BASF LANXESS Bayer AG UBS AG RUS DEU UKR Geoff Haire Show more
TradFi, Market Report
14:38 09.12.2024
UBS Maintains Neutral Rating on Bayer with Target Price of 22 Euros
UBS has maintained a "Neutral" rating for Bayer, setting a target price of 22 euros. Analyst Geoff Haire highlighted that a potential ceasefire between Russia and Ukraine could lower gas prices, benefiting companies like BASF, Covestro, Lanxess, and Yara in the European chemical sector.
finanzen.net
United States Dollar Euro Covestro AG BASF LANXESS Bayer AG UBS AG RUS DEU UKR Geoff Haire Show more
TradFi, Market Report
14:28 09.12.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Central Bank Actions Banking Regulations Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Mergers & Acquisitions Cryptocurrency & Blockchain Regulations Cryptocurrency Developments Blockchain Technology Adoption Market Analysis and Predictions Anti-Money Laundering (AML) Regulations Emerging Startups Cryptocurrency Regulations Inflation Rates & CPI Data SEC & Financial Compliance Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN CHN IND SGP DNK CAN NGA FIN COL AUT VGB LIE TUR
Companies:
Credit Suisse Real Estate Fund Siat BlackRock, Inc. Coinbase Global, Inc. Solana USD Ethereum USD Ripples USD Tesla, Inc. Fidelity Contrafund Cardano USD Apple Inc. NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc End Federal Reserve USD MicroStrategy Incorporated Crypto.com Staked ETH USD
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Thomas Jordan Gary Gensler Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.